Tritonix.ai

News / Taiwan / cnyes

Xufu August Revenue Soars 187.52% Year-over-Year

Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-08

4119

Xufu (4119) reported August 2026 revenue of NT$149 million, a 187.52% year-over-year surge, with year-to-date revenue growth at 14.21%.

What Happened

Revenue Performance: Xufu (4119) announced August 2026 revenue of NT$149 million, representing a massive 187.52% year-over-year increase, despite a 21.93% monthly decline.

Year-to-Date Results: For the first eight months of 2026, the company recorded a cumulative revenue of NT$988 million, reflecting a steady year-to-date growth of 14.21%.

Market Context: The stock is currently trading at NT$53.8, with a 4.44% decline over the past five days, showing little correlation with the 0.01% gain in the biotech and medical index.

Business Profile: Xufu is a key player in the biotech and medical industry, focusing on the manufacturing, processing, and sale of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals.

Read original

More in Health Technology

Sandoz CEO Warns Trump's Generic Drug Tariffs Will Burden U.S. Patients

Health Technology · cnbc · 2026-09-08

Sandoz CEO Richard Saynor warns that proposed U.S. tariffs on generic medicines could force manufacturers to hike prices or halt supply, impacting millions of patients.

SDZ-CH, NVO, NVO, NVS

AstraZeneca Reports Positive Late-Stage Data for Tozorakimab in COPD Treatment

Health Technology · cnbc · 2026-09-08

AstraZeneca's experimental COPD drug, tozorakimab, showed significant efficacy in late-stage trials, bolstering the company's multi-billion dollar sales outlook.

AZN, AZN, SNY, GSK, GILD, SNY, REGN, GSK, IBB

Taiwan Biotech Firms Joyful: Fortune and PharmaEssentia Report Record August Revenues

Health Technology · economic_daily · 2026-09-08

Taiwanese biotech companies Fortune and PharmaEssentia posted record-breaking August revenues, driven by strong product sales and international market expansion.

Latest in Taiwan

Analysts Trim 2026 EPS Forecast for Compeq (2313-TW) to NT$7.38

Electronic Technology · cnyes · 2026-09-08

Following a recent FactSet survey, analysts have lowered their 2026 EPS estimates for Compeq (2313-TW) to a median of NT$7.38, with a target price set at NT$322.5.

2313

元山 August Revenue Rises 2.36%; Liquid Cooling Lab Set for Q3 Launch

Electronic Technology · economic_daily · 2026-09-08

Yuan Shan Technology reported a 2.36% year-on-year increase in August revenue, with its new liquid cooling lab expected to launch by the end of Q3 to capture AI demand.

CTBC Financial Subsidiaries Plan $127M Combined Bid for HanTest IPO

Electronic Technology · cnyes · 2026-09-08

CTBC Bank and Taiwan Life Insurance have announced plans to invest up to NT$4.1 billion in the upcoming IPO of semiconductor equipment firm HanTest.

2891, 7856

Eastek Hits Daily Limit Up at Open: What's Driving the Surge?

Electronic Technology · economic_daily · 2026-09-08

Eastek shares surged to the daily limit immediately upon opening today, drawing significant investor attention to the catalysts behind the sudden rally.